ASCO-GI – a second colorectal win for Bristol's combo
Opdivo and Yervoy succeed again, but the US path remains unclear.
ASCO-GI – ALX resurrects evorpacept
The company reveals fresh biopsy status as a primary endpoint, and declares Aspen-06 a win.
ASCO-GI – Exelixis’s son of Cabometyx disappoints
The company might need something better to replace its ageing blockbuster.
Innate challenges Pfizer in Nectin-4
While Cogent joins the FGFR party.
ASCO-GI – no masking Xilio's setback
Poor efficacy clouds prospects for the company's "improved" Yervoy.
Nuvalent sets out its two-pronged strategy
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
